ArticleCancer discovery2021
ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 88 citations in OpenAlex.
- Supratentorial ependymoma: a comprehensive review of molecular classification, management strategies, and clinical outcomes (Part II of pediatric ependymomas across compartments).Journal of neuro-oncology · 2026Review
- Clinical, surgical, and molecular features of pediatric supratentorial ependymomas: a single-institution experience.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- A brief history of ependymoma.Neuro-oncology · 2026Review
- Article
- Article
- Article
- A systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies.Frontiers in oncology · 2026Review
- Use of Automated BaseScope Assay on the Leica BOND RX.Methods in molecular biology (Clifton, N.J.) · 2026Article
- B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Synthetic ZFTA fusions pinpoint disordered protein domain acquisition as a mechanism of brain tumorigenesis.Nature cell biology · 2025Article
- Fusion oncoproteins acquire condensate propensity to initiate tumour formation.Nature cell biology · 2025Article
- EphB2-Targeting Monoclonal Antibodies Exerted Antitumor Activities in Triple-Negative Breast Cancer and Lung Mesothelioma Xenograft Models.International journal of molecular sciences · 2025Article
- Real-World Data Analysis of Genomic Alterations Detected by a Dual DNA-RNA Comprehensive Genomic Profiling Test.Cancer science · 2025Article
- Cancer cells' chamber of secrets: the link between micronuclei, chromothripsis and malignancy.Open biology · 2025Review
- Advances in molecular prognostication and treatments in ependymoma.Journal of neuro-oncology · 2025Review
- Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Biglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling.Acta neuropathologica communications · 2025Article
- Optimizing outcomes in intracranial ependymoma: a contemporary review.Frontiers in oncology · 2025Review
- Aberrant histone modifications in pediatric brain tumors.Frontiers in oncology · 2025Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 10 institutions in 5 countries.
Amir Arabzade *Department of Chemical and Biomolecular Engineering, Rice University, Houston, Texas.
Yanhua Zhao *Department of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.
Srinidhi Varadharajan *Department of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.ORCID 0000-0002-2033-0758
Hsiao-Chi Chen *Department of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.ORCID 0000-0002-7505-6119
Selin JessaQuantitative Life Sciences, McGill University, Montreal, Quebec, Canada.ORCID 0000-0003-4192-6523
Bryan RivasDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.
Austin J StuckertDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.ORCID 0000-0002-5938-7495
Minerva SolisDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.
Alisha KardianDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.
Dana TlaisDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.ORCID 0000-0002-0060-8070
Brian J GolbournDepartment of Neurological Surgery, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Ann-Catherine J StantonDepartment of Neurological Surgery, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Yuen San ChanTherapeutic Innovation Center at Baylor College of Medicine, Houston, Texas.
Calla OlsonTherapeutic Innovation Center at Baylor College of Medicine, Houston, Texas.
Kristen L KarlinTherapeutic Innovation Center at Baylor College of Medicine, Houston, Texas.
Kathleen KongTherapeutic Innovation Center at Baylor College of Medicine, Houston, Texas.
Robert KuppCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, England.
Baoli HuDepartment of Neurological Surgery, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0002-2737-6871
Sarah G InjacDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.ORCID 0000-0002-6389-369X
Madeline NgoDepartment of Chemical and Biomolecular Engineering, Rice University, Houston, Texas.ORCID 0000-0003-3610-6475
Peter R WangDepartment of Chemical and Biomolecular Engineering, Rice University, Houston, Texas.
Luz A De LeónDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.
Felix SahmHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0001-5441-1962
Daisuke KawauchiHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0002-1254-9725
Stefan M PfisterHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0002-5447-5322
Charles Y LinTherapeutic Innovation Center at Baylor College of Medicine, Houston, Texas.
H Courtney HodgesTherapeutic Innovation Center at Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-4441-497X
Irtisha SinghDepartment of Molecular and Cellular Medicine, College of Medicine, Texas A&M University Health Science Center, Bryan, Texas.
Thomas F WestbrookTherapeutic Innovation Center at Baylor College of Medicine, Houston, Texas.
Murali M ChintagumpalaDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.
Susan M BlaneyDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.
Donald W ParsonsDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.
Kristian W PajtlerHopp-Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Sameer AgnihotriDepartment of Neurological Surgery, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Richard J GilbertsonCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, England.ORCID 0000-0001-7539-9472
Joanna YiDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas.
Nada JabadoQuantitative Life Sciences, McGill University, Montreal, Quebec, Canada.
Claudia L KleinmanQuantitative Life Sciences, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-5158-7126
Kelsey C BertrandDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas. stephen.mack@stjude.org deneen@bcm.edu stephen.mack@stjude.org.
Benjamin DeneenCancer and Cell Biology Program, Baylor College of Medicine, Dan L. Duncan Cancer Center, Houston, Texas. stephen.mack@stjude.org deneen@bcm.edu stephen.mack@stjude.org.
Stephen C MackDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, Texas Children's Cancer and Hematology Centers, Dan L. Duncan Cancer Center, Houston, Texas. stephen.mack@stjude.org deneen@bcm.edu stephen.mack@stjude.org.ORCID 0000-0001-9620-4742
Baylor College of Medicine · USChildren's Cancer Center · USChildren's Hospital of Pittsburgh · USGerman Cancer Research Center · DECancer Research UK Cambridge Center · GBMcGill-Queen's University Press · CARice University · USThe University of Texas MD Anderson Cancer Center · USJewish General Hospital · CATexas A&M Health Science Center · US
Funding
PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAMK12CA090433 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CARL E ALLEN, Donald W. Parsons · 2002 to 2026
$18.5MInitiative for Maximizing Student Development (IMSD) ProgramR25GM056929 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI PEREIRA, FRED A · 1998 to 2023
$12.4MYEARS 19 - 23: BCM POST-BACCALAUREATE RESEARCH EDUCATION PROGRAMR25GM069234 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI PEREIRA, FRED A · 2003 to 2024
$7.5MIntegrative bioinformatics and functional characterization of oncogenic driver aberrations in cancerU01CA217842 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DENEEN, BENJAMIN, MILLS, GORDON B. · 2017 to 2021
$3.6MMOLECULAR DISSECTION OF SEIZURE MICROENVIRONMENT IN MALIGNANT GLIOMAR01CA223388 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DENEEN, BENJAMIN, NOEBELS, JEFFREY · 2018 to 2022
$3.5MNovel cellular regulatory mechanisms governing SWI/SNF activityR35GM137996 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI Hamilton Courtney Hodges · 2020 to 2026
$2.9MDeciphering the Role of Aberrant Endogenous Retroviral Expression in Onco-histone Driven GliomaR01NS116361 · NINDS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Stephen C Mack · 2021 to 2026
$2.5MDynamic effects of cancer mutations on the mammalian SWI/SNF ATPase BrgR00CA187565 · NCI · BAYLOR COLLEGE OF MEDICINE · PI HODGES, HAMILTON COURTNEY · 2017 to 2019
$747kCancer Research UK 22492Cancer Research UK 26398Cancer Research UK 28598NCI NIH HHS K12 CA090433NCI NIH HHS R00 CA187565NCI NIH HHS R01 CA223388NCI NIH HHS U01 CA217842NIGMS NIH HHS R25 GM056929NIGMS NIH HHS R25 GM069234NIGMS NIH HHS R35 GM137996NINDS NIH HHS R01 NS116361
Abstract
More than 60% of supratentorial ependymomas harbor a
Indexed as
AnimalsDisease Models, AnimalDNA-Binding ProteinsEpendymomaMiceSupratentorial NeoplasmsTranscription Factor RelATranscription Factors2700081o15rik protein, mouseDNA-Binding ProteinsRELA protein, humanTranscription Factor RelATranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.